Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease

CARMIEL, Israel and BOSTON, Feb. 24, 2022 -- (Healthcare Sales & Marketing Network) -- Protalix BioTherapeutics, Inc. (NYSE: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeu... Biopharmaceuticals, Regulatory Protalix BioTherapeutics, Chiesi , Fabry disease, pegunigalsidase alfa
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news